SCHEMBL6841538

SCHEMBL6841538

NS(=O)(=O)c1cc(F)cc(-c2ncccc2-c2cc(F)cc(F)c2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 11/20 0.45
CA2 P00918 11/20 0.45
PTGS2 P35354 3/20 0.42
PTGS1 P23219 2/20 0.42
TDP2 O95551 1/20 0.41
NSD2 O96028 1/20 0.41
ABL1 P00519 1/20 0.41
PLCG1 P19174 1/20 0.41
CES1 P23141 1/20 0.41
PAX8 Q06710 1/20 0.41
RIN1 Q13671 1/20 0.41
GAA P10253 1/20 0.41
CA12 O43570 1/20 0.40
CA9 Q16790 1/20 0.40
CTSL P07711 1/20 0.38
PTPRC P08575 1/20 0.38
CTSS P25774 1/20 0.38
PTPN13 Q12923 1/20 0.38
MEN1 O00255 1/20 0.38
THRB P10828 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6837797 0.92 PTGS2 (0.52) CA1CA2PTGS2PTGS1CA12
SCHEMBL6835856 0.92 PTGS2 (0.52) CA1CA2PTGS2PTGS1CA12
SCHEMBL6841006 0.91 CA1 (0.41) CA1CA2PTGS2PTGS1CA12
SCHEMBL6834914 0.91 CA1 (0.41) CA1CA2PTGS2PTGS1CA12
SCHEMBL6837039 0.91 CA1 (0.42) CA1CA2PTGS2PTGS1TDP2
SCHEMBL6834947 0.91 CHRNA7 (0.43) CA1CA2PTGS2PTGS1CA12
SCHEMBL6835212 0.89 CA1 (0.44) CA1CA2PTGS2PTGS1CA12
SCHEMBL6840518 0.89 CA1 (0.44) CA1CA2PTGS2PTGS1CA12
SCHEMBL6837521 0.89 PTGS2 (0.43) CA1CA2PTGS2PTGS1CA12
SCHEMBL6833679 0.89 PTGS2 (0.49) CA1CA2PTGS2PTGS1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040138261-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2004-07-15 US disclosed
US-6673818-B2 TREATING CYCLOOXYGENASE-2 MEDIATED DISORDERS, SUCH AS ARTHRITIS, PAIN, FEVER AND CANCER PHARMACIA CORPORATION 2004-01-06 US disclosed
US-20030149078-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-08-07 US disclosed
US-20030032657-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-02-13 US disclosed
EP-1251126-A2 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation Pharmacia Corporation (US) 2002-10-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138261-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 CA1 2085/4885CA2 3175/4885PTGS2 10/4885
US-20030149078-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 CA1 2085/4885CA2 3175/4885PTGS2 10/4885
US-20030032657-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 CA1 2085/4885CA2 3175/4885PTGS2 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.